Clinical Trial

Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention

Study acronym: APLABE-PCI
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The APLABE-PCI is a single-center, randomized, open-label, controlled, dose-escalating, parallel-group study, which is designed to assess the anti-platelet effect of berberine in approximately 64 patients receiving aspirin and clopidogrel who are at \> 8 but ≤ 40 weeks after percutaneous coronary intervention.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-12-14; most recent amendment 2025-11-16.
Status change: Not Yet Recruiting → Recruiting 2018-10-01
Trial Details
NCT Number NCT03378934
Lead Sponsor Peking Union Medical College Hospital
Conditions Coronary Artery Disease, Percutaneous Coronary Intervention
Enrollment 64 participants
Start Date 2018-09-26
Primary Completion 2026-06 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-11-19